| Overview |
| bs-1230R-Cy5.5 |
| ABL2 Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Dog, Pig, Horse, Rabbit |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human ABL2 |
| 935-1050/1182 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 27 |
| Cytoplasm |
| Abelson murine leukemia viral oncogene homolog 2; Abelson related gene protein; Tyrosine kinase ARG; ABLL;ARG;Tyrosine protein kinase ABL2; v abl Abelson murine leukemia viral oncogene homolog 2; ABL2_HUMAN; Abelson tyrosine-protein kinase 2; Tyrosine-protein kinase ARG. |
| ABL2 (or ARG) is a nonreceptor cytoplasmic tyrosine kinase which is closely related to but distinct from ABL1. The similarity of ABL1 and ABL2 includes the tyrosine kinase domains and extends amino-terminal to include the SH2 and SH3 domains. ABL2 is expressed in both normal and tumor cells. It is involved in translocation with the ETV6 gene in human leukemia and has an altered expression in several human carcinomas. Two isoforms of ABL2 with different N-termini (1A and 1B) have been identified. The C-terminal domain of ABL2 contains two F-actin-binding sequences that perform a number of actions related to cell morphology and motility by interacting with actin filaments. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz